Nifuroxazide Boosts the Anticancer Efficacy of Palbociclib-Induced Senescence by Dual Inhibition of STAT3 and CDK2 in Triple-Negative Breast Cancer

Investigators reported that combining palbociclib with the STAT3 inhibitor nifuroxazide uncoupled senescence-associated secretory phenotype production from senescence-associated cell cycle exit.